CA2759873A1 - Influenza hemagglutinin compositions and uses thereof - Google Patents

Influenza hemagglutinin compositions and uses thereof Download PDF

Info

Publication number
CA2759873A1
CA2759873A1 CA2759873A CA2759873A CA2759873A1 CA 2759873 A1 CA2759873 A1 CA 2759873A1 CA 2759873 A CA2759873 A CA 2759873A CA 2759873 A CA2759873 A CA 2759873A CA 2759873 A1 CA2759873 A1 CA 2759873A1
Authority
CA
Canada
Prior art keywords
ectodomain
influenza
seq
amino acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2759873A
Other languages
English (en)
French (fr)
Inventor
Martin Bachmann
Andrea Jegerlehner
Philippe Saudan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytos Biotechnology AG
Original Assignee
Cytos Biotechnology AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology AG filed Critical Cytos Biotechnology AG
Publication of CA2759873A1 publication Critical patent/CA2759873A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2759873A 2009-04-30 2010-04-30 Influenza hemagglutinin compositions and uses thereof Abandoned CA2759873A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09159262 2009-04-30
EP09159262.6 2009-04-30
PCT/EP2010/055944 WO2010125202A1 (en) 2009-04-30 2010-04-30 Influenza hemagglutinin compositions and uses thereof

Publications (1)

Publication Number Publication Date
CA2759873A1 true CA2759873A1 (en) 2010-11-04

Family

ID=42790940

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2759873A Abandoned CA2759873A1 (en) 2009-04-30 2010-04-30 Influenza hemagglutinin compositions and uses thereof

Country Status (9)

Country Link
US (1) US20120263743A1 (https=)
EP (1) EP2424570A1 (https=)
JP (1) JP2012525134A (https=)
CN (1) CN102573915B (https=)
AU (1) AU2010243490A1 (https=)
CA (1) CA2759873A1 (https=)
NZ (1) NZ596058A (https=)
SG (1) SG175382A1 (https=)
WO (1) WO2010125202A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106822887A (zh) * 2017-01-26 2017-06-13 中国科学院微生物研究所 一种流感病毒四价亚单位疫苗及其应用
SG11202109850SA (en) 2019-03-13 2021-10-28 Generation Bio Co Non-viral dna vectors and uses thereof for expressing fviii therapeutics

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2327382T3 (es) * 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
DE60234375D1 (de) * 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
ES2316628T3 (es) * 2001-11-07 2009-04-16 Cytos Biotechnology Ag Disposicion ordenada de antigenos que comprende rankl para el tratamiento de enfermedades oseas.
US7138252B2 (en) * 2002-07-17 2006-11-21 Cytos Biotechnology Ag Molecular antigen arrays
RU2375076C2 (ru) * 2003-07-10 2009-12-10 Цитос Биотехнологи Аг Укомплектованные вирусоподобные частицы
CN101023103A (zh) * 2004-09-21 2007-08-22 赛托斯生物技术公司 包含ap205外壳蛋白和抗原性多肽的融合蛋白的病毒样颗粒
MX2007003171A (es) * 2004-09-21 2007-05-23 Cytos Biotechnology Ag Particulas tipo virus que comprenden una proteina de fusion de la proteina de cubierta de ap205 y un polipeptido antigenico.
US8420102B2 (en) * 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
CA2615658A1 (en) * 2005-07-19 2007-01-25 Dow Global Technolgies Inc. Recombinant flu vaccines
AU2006279323B2 (en) * 2005-08-16 2013-08-01 Merck Sharp & Dohme Corp. Influenza recombinant subunit vaccine
KR101359723B1 (ko) * 2005-10-18 2014-02-05 노바백스, 인코포레이티드 기능성 인플루엔자 바이러스 유사 입자들
CA2636139A1 (en) * 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
CU23576A1 (es) * 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
CN101394864A (zh) * 2006-03-07 2009-03-25 法克斯因内特公司 包含血细胞凝集素的组合物、制造其的方法与使用其的方法

Also Published As

Publication number Publication date
JP2012525134A (ja) 2012-10-22
SG175382A1 (en) 2011-12-29
EP2424570A1 (en) 2012-03-07
NZ596058A (en) 2013-08-30
CN102573915A (zh) 2012-07-11
WO2010125202A1 (en) 2010-11-04
CN102573915B (zh) 2015-02-18
US20120263743A1 (en) 2012-10-18
AU2010243490A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
US12605454B2 (en) Modified virus-like particles of CMV
RU2540871C2 (ru) Самоорганизующиеся пептидные наночастицы, полезные в качестве вакцин
AU2006224529B2 (en) Cat allergen fusion proteins and uses thereof
AU2022291431B2 (en) Treatment of canine atopic dermatitis
AU2005286475A1 (en) Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
EP1603590A2 (en) Influenza virus vaccine
Park et al. Chemical and biological conjugation strategies for the development of multivalent protein vaccine nanoparticles
US10898569B2 (en) Treatment of peanut allergy
WO2016087863A1 (en) Vaccines based on hepatitis b core antigens
US20120263743A1 (en) Influenza hemagglutinin compositions and uses thereof
WO2025073874A1 (en) Vaccine composition comprising m2e nanoparticles and ha1 protein
WO2010122164A1 (en) VIRUS-LIKE PARTICLES OF BACTERIOPHAGE φCB5
RU2852174C1 (ru) Рекомбинантная вакцина против вируса гриппа а человека и способ ее получения
WO2007039458A2 (en) Hiv peptide conjugates and uses thereof
HK40077650A (zh) Cmv的修饰病毒样颗粒
BR112017008266B1 (pt) Partícula semelhante a vírus (vlp) modificada do vírus do mosaico do pepino (cmv) e composição farmacêutica
BR122024008858A2 (pt) Uso de uma partícula semelhante a vírus (vlp) modificada do vírus do mosaico do pepino (cmv), ou uma composição compreendendo a referida partícula no tratamento de uma doença, distúrbio ou condição em um animal ou ser humano

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160502